Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.01M$4.01Mderived+74.8% vs Q4 2016 Net Income-$237.06K-$237.06KderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,523,248+77.7% Operating Incomederived-$239,306N/M Operating Cash Flowderived$5,210N/M Free Cash Flowderived-$7,723N/M Margins · derivedGross margin63.0%+1.0 pt vs Q4 2016
Operating margin-6.0%+10.1 pt vs Q4 2016
Net margin-5.9%+9.5 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 8, 2018 · 67 d after period end